chr7:140453135:> Detail (hg19) (BRAF)

Information

Genome

Assembly Position
hg19 chr7:140,453,135-140,453,137
hg38 chr7:140,753,335-140,753,337 

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
17-AAG is a HSP90 inhibitor MMMP Detail
In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epige... MMMP Detail
Inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (Sorafenib) or by selective... MMMP Detail
The growth rate of melanoma cells (but not colon carcinoma) harboring BRAF V600E is inhibited by BRA... MMMP Detail
C-Raf siRNA knockdown results in decreased viability of YULAC (B-Raf(V600K)) and YUROB (B-Raf(WT)) m... MMMP Detail
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF muta... MMMP Detail
Anti-melanoma efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF(V600E) mutational st... MMMP Detail
U0126: MEK inhibitor MMMP Detail
AZ628: RAF selective inhibitor MMMP Detail
Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which ... MMMP Detail
Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which ... MMMP Detail
Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which ... MMMP Detail
Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Oncogenic mutationally activated BRAF acts through... MMMP Detail
CI-1040 is a MEK inhibitor. Mutation of BRAF is associated with enhanced and selective sensitivity t... MMMP Detail
PLX 4720 is a BRAF inhibitor with high selectivity for mutated BRAF V600E (compared to wild type) MMMP Detail
17-AAG is a HSP90 inhibitor that works against melanoma cells independently of the BRAF mutational s... MMMP Detail
No objective responses were observed, either in BRAF mutant or wild type tumors MMMP Detail
When present, BRAF(V599E) appears to be essential for melanoma cell viability and transformation and... MMMP Detail
U0126 is a MEK inhibitor. When BRAF is mutated (V600E), targeting MEK is more effective than targeti... MMMP Detail
Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. When BRAF is mutated (V600E), targeting MEK (with ... MMMP Detail
BRAF mutational status has no impact on the response to this treatment MMMP Detail
Tumor response was not associated with BRAF mutation. Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibit... MMMP Detail
Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Tumor response was minimal both in mutated and wil... MMMP Detail
RAF 265 is a BRAF inhibitor MMMP Detail
Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor MMMP Detail
AZ628 is a BRAF inhibitor MMMP Detail
PLX4032 is a BRAF inhibitor with high selectivity for mutated BRAF V600E MMMP Detail
Isolated limb infusion model. p16INK4a expression and absence of activated B-RAF are independent pre... MMMP Detail
Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor MMMP Detail
U0126: MEK inhibitor. ABT-737: BH3 mimetic. Treatment of B-RAF mutant human melanoma with a MEK inhi... MMMP Detail
PLX4032 is a BRAF inhibitor with high selectivity for mutated BRAF V600E. While PLX4032 has antitumo... MMMP Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
Genome
hg19
Position
chr7:140,453,135-140,453,137
Variant Type
snv
Reference Amino Acid
V
Alternative Amino Acid
E
Genome browser